Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00637832
Other study ID # CDR0000588042
Secondary ID USCTU-SCHRIFT-06
Status Terminated
Phase Phase 2
First received
Last updated
Start date April 1, 2008
Est. completion date January 6, 2015

Study information

Verified date December 2021
Source University of Southampton
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Giving rituximab together with combination chemotherapy and yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy and yttrium Y 90 ibritumomab tiuxetan works in treating patients with relapsed follicular non-Hodgkin lymphoma.


Description:

OBJECTIVES: Primary - To evaluate the response rates in patients with relapsed follicular non-Hodgkin lymphoma treated with short-duration rituximab and combination chemotherapy (R-chemo) followed by rituximab and yttrium Y 90 ibritumomab tiuxetan. Secondary - To evaluate the duration of response in patients treated with this regimen. - To evaluate the quality of response in order to determine the conversion rate from partial response to complete response in patients treated with this regimen. - To evaluate the toxicity of yttrium Y 90 ibritumomab tiuxetan when administered after 3 courses of R-chemo. OUTLINE: This is a multicenter study. - Chemoimmunotherapy (R-CHOP or R-CVP): Patients receive R-CHOP comprising rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisolone on days 1-5. Alternatively, patients who have already been exposed to prior tolerance doses of anthracyclines receive R-CVP comprising rituximab IV, cyclophosphamide IV, and vincristine IV on day 1 and oral prednisolone on days 1-5. Treatment repeats every 3 weeks for up to 3 courses. Patients with objective evidence of response on CT scan or those with < 25% bone marrow involvement and no signs of bone marrow hypocellularity (< 15%) on bone marrow biopsy proceed to radioimmunotherapy. - Radioimmunotherapy: Four to 6 weeks after completion of R-CHOP or R-CVP, patients receive rituximab IV followed no more than 4 hours later by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes. After completion of study therapy, patients are followed periodically for up to 5 years.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date January 6, 2015
Est. primary completion date January 6, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS: - Histologically confirmed grade 1, 2, or 3 follicular non-Hodgkin lymphoma - Stage II, III, or IV disease (according to the Ann Arbor staging system) - CD20-positive disease - Initial disease bulk = 10 cm - In first or second relapse after prior treatment with a rituximab-containing chemotherapy regimen (R-chemo) or chemotherapy alone - Relapse must have occurred = 6 months after completion of R-chemo - Relapse that occurred < 6 months after completion of chemotherapy alone allowed - Has at least one of the following symptoms requiring initiation of treatment: - Nodal mass > 5 cm in its greater diameter - B symptoms - Elevated serum lactate dehydrogenase (LDH) or ß2-microglobulin - Involvement of = 3 nodal sites (each with a diameter > 3 cm) - Symptomatic splenic enlargement - Compressive syndrome - No primary refractory disease - No large pleural or peritoneal effusions - No CNS disease PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - Life expectancy = 6 months - Absolute granulocyte count = 1,500/mm³ - Platelet count = 1,000/mm³ - Serum creatinine < 1.5 times upper limit of normal (ULN) - Total bilirubin < 1.5 times ULN - AST < 5 times ULN - No active obstructive hydronephrosis - No evidence of active infection requiring IV antibiotics - No advanced heart disease or other serious illness that would preclude study evaluation - No known HIV infection - No human anti-mouse antibody (HAMA) reactivity - No known hypersensitivity to murine antibodies or proteins - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 12 months after completion of study treatment - No other prior malignancy, except for adequately treated skin cancer, cervical cancer in situ, or other cancer for which the patient has been disease-free for 5 years PRIOR CONCURRENT THERAPY: - See Disease Characteristics - At least 4 weeks since prior investigational drugs and recovered - No prior radioimmunotherapy

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
rituximab

Drug:
cyclophosphamide

doxorubicin hydrochloride

prednisolone

vincristine sulfate

Radiation:
yttrium Y 90 ibritumomab tiuxetan


Locations

Country Name City State
United Kingdom Saint Bartholomew's Hospital London
United Kingdom Christie Hospital Manchester England
United Kingdom Mount Vernon Cancer Centre at Mount Vernon Hospital Northwood England
United Kingdom Dorset Cancer Centre Poole Dorset England
United Kingdom Southampton General Hospital Southampton England

Sponsors (1)

Lead Sponsor Collaborator
University of Southampton

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rate, including combined complete response and partial response
Secondary Time to disease progression
Secondary Time to next treatment
Secondary Response duration in patients with responding disease
Secondary Safety
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1